Skip to main content

Table 1 Relationship between MBD1 expression and clinicopathological factors of patients with GBC

From: MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine

Parameter No. of patients MBD1 (low) MBD1 (high) Spearman correlation P value
Sex 0.107 0.333
 Male 45 16 (35.6%) 29 (64.4%)   
 Female 39 10 (25.6%) 29 (74.4%)   
Age (years) − 0.020 0.859
 < 60 40 12 (30.0%) 28 (70.0%)   
 ≥ 60 44 14 (31.9%) 30 (68.1%)   
Tumor size (cm) 0.085 0.441
 ≤ 5 53 18 (33.9%) 35 (66.1%)   
 > 5 31 8 (25.8%) 23 (74.2%)   
Differentiation grade 0.182 0.098
 Well-moderate 31 13 (41.9%) 18 (58.1%)   
 Poor-undifferentiated 53 13 (24.5%) 40 (75.5%)   
T stage 0.036 0.742
 T1–T3 56 18 (32.1%) 38 (67.9%)   
 T4 28 8 (28.6%) 20 (71.4%)   
Lymph node status 0.378 < 0.001
 Negative 55 24 (43.6%) 31 (56.4%)   
 Positive 29 2 (6.9%) 27 (93.1%)   
Distant metastasis status 0.299 0.006
 M0 53 22 (41.5%) 31 (58.5%)   
 M1 31 4 (12.9%) 27 (87.1%)   
TNM stage 0.287 0.008
 I–II 34 16 (47.1%) 18 (52.9%)   
 III–IV 50 10 (20.0%) 40 (80.0%)   
  1. MBD1 Low: negative/weak MBD1 expression; MBD1 High: moderate/strong MBD1 expression; T stage and TNM stage were defined by the AJCC 8th edition; P-values were derived by Spearman rank correlation; all statistical tests were two-sided